|
|
 |
|
Viewing report
|
|
|
|
Amylin Pharmaceuticals, Inc.: SWOT Analysis & Company Profile
Business Review, Sep 2010, Pages: 25
Synopsis
Business Review’s Amylin Pharmaceuticals, Inc. contains a company overview, key facts, locations and subsidiaries, news and events as well as a SWOT analysis of the company.
Summary
This SWOT Analysis company profile is a crucial resource for industry executives and anyone looking to quickly understand the key information concerning Amylin Pharmaceuticals, Inc.’s business.
Business Review’s “Amylin Pharmaceuticals, Inc. SWOT Analysis & Company Profile” reports utilize a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format.
Business Review strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.
Scope
- Examines and identifies key information and issues about (Amylin Pharmaceuticals, Inc.) for business intelligence requirements
- Studies and presents Amylin Pharmaceuticals, Inc.’s strengths, weaknesses, opportunities (growth potential) and threats (competition). Strategic and operational business information is objectively reported.
- The profile contains business operations, the company history, major products and services, prospects, key competitors, structure and key employees, locations and subsidiaries.
Reasons To Buy
- Quickly enhance your understanding of the company.
- Obtain details and analysis of the market and competitors as well as internal and external factors which could impact the industry.
- Increase business/sales activities by understanding your competitors’ businesses better.
- Recognize potential partnerships and suppliers.
- Obtain yearly profitability figures
Key Highlights
Amylin Pharmaceuticals, Inc. (Amylin) is an US based biopharmaceutical company engages in the development and marketing of innovative medicines for the treatment of diabetes, obesity and other diseases. It markets two medicines namely, BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection to treat diabetes. Through a network of wholesale distributors, Amylin sells its products to healthcare providers, managed healthcare organizations, wholesalers and pharmacies, government purchasers and other third-party players. Amylin also entered into strategic agreement and collaboration with various companies such as Alkermes, Inc., Biocon Limited, Eli Lilly and Company, Psylin Neurosciences, Inc., and Takeda Pharmaceutical Company Limited develop novel treatments for the patients. The company is headquartered in California, the US.
|
|
|
|
